Orion Biotech Opportunities EBIT

Orion Biotech Opportunities (ORIA) currently reports a EBIT of $-900K as of December 2022. That compares with $-630K in the prior-year period — down 43.2% year over year. That is above the sector sector average of $-69M. Use the charts on this page to explore Orion Biotech Opportunities's EBIT history and peer comparisons.

Orion Biotech Opportunities's EBIT decreased from $-630K to $-900K — a 43.2% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Orion Biotech Opportunities's EBIT of $-900K is higher than the its sector sector average of $-69M. That is roughly 98.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Orion Biotech Opportunities reported $-900K in EBIT as of December 2022. That compares with $-630K in the prior-year period — down 43.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-900K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-69M. From there, open related valuation or income-statement pages for Orion Biotech Opportunities, and consider following ORIA for alerts when major investors trade the stock.